Clinical Policy: Quinine Sulfate (Qualaquin)
Reference Number: CP.PCH.10
Effective Date: 12.01.18
Last Review Date: 05.20
Line of Business: Commercial, HIM

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Quinine sulfate (Qualaquin®) is an antimalarial drug.

FDA Approved Indication(s)
Qualaquin is indicated for treatment of uncomplicated *Plasmodium falciparum* malaria.

Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented.

Limitation(s) of use: Qualaquin is not approved for:
- Treatment of severe or complicated *P. falciparum* malaria
- Prevention of malaria
- Treatment or prevention of nocturnal leg cramps

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Qualaquin is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Malaria (must meet all):
      1. Diagnosis of one of the following (a or b):
         a. Uncomplicated *Plasmodium falciparum* malaria;
         b. *Plasmodium vivax* malaria (off-label);
      2. Failure of a formulary antimalarial agent (e.g., atovaquone-proguanil, Coartem®, chloroquine, hydroxychloroquine, mefloquine), unless clinically significant adverse effects are experienced, all are contraindicated, or the causative species is resistant to all formulary antimalarial agents;
      3. Dose does not exceed 1,944 mg (6 capsules) per day.
      Approval duration: 7 days
   
   B. Babesiosis (off-label) (must meet all):
      1. Diagnosis of babesiosis;
      2. Dose does not exceed 1,944 mg (6 capsules) per day.
      Approval duration: Duration of request or 10 days (whichever is less)
C. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and HIM.PHAR.21 for health insurance marketplace.

II. Continued Therapy
A. Malaria or Babesiosis (off-label)
   1. Re-authorization is not permitted. Member must meet the initial approval criteria. 
   Approval duration: Not applicable

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy. 
   Approval duration: Duration of request or 7 days (whichever is less); or 
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial and HIM.PHAR.21 for health insurance marketplace.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial and HIM.PHAR.21 for health insurance marketplace or evidence of coverage documents;
B. Prevention of malaria;
C. Treatment or prevention of nocturnal leg cramps.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   CDC: Centers for Disease Control and Prevention 
   FDA: Food and Drug Administration 
   G6PD: glucose-6-phosphate dehydrogenase 
   HUS/TTP: hemolytic uremic syndrome/thrombotic thrombocytopenic purpura

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>atovaquone-proguanil</td>
<td>Adults: 1 gram atovaquone/400 mg proguanil hydrochloride PO QD for 3 days</td>
<td>See dosing regimen</td>
</tr>
<tr>
<td>(Malarone®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Dose Limit/Maximum Dose</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Coartem® (artemether/lumefantrine)</td>
<td>Adults: 80 mg artemether/480 mg lumefantrine PO initially, then a second dose 8 hours later, then 1 dose PO twice daily (morning and evening) for the next 2 days for a total course of 24 tablets</td>
<td>8 tablets/day (total of 6 doses over 3 days)</td>
</tr>
<tr>
<td>chloroquine (Aralen®)</td>
<td>Adults: 1,000 mg (600 mg base) PO, then 500 mg (300 mg base) PO in 6 to 8 hours, then 500 mg (300 mg base) PO QD for 2 days.</td>
<td>1 g (600 mg base) PO as initial dose(s) for malaria treatment; otherwise, 500 mg/dose (300 mg base/dose) PO.</td>
</tr>
<tr>
<td>hydroxychloroquine (Plaquenil®)</td>
<td>Adults: 800 mg (620 mg base) PO, then 400 mg (310 mg base) PO at 6, 24, and 48 hours after the initial dose for a total dose of 2 g (1.55 g base)</td>
<td>See dosing regimen</td>
</tr>
<tr>
<td>mefloquine</td>
<td>Adults: 1,250 mg (administered as five 250 mg tablets) PO as a single dose. Alternatively, 750 mg PO as the initial dose, then 500 mg PO 6 to 12 hours later</td>
<td>See dosing regimen</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s):
  - Prolongation of QT interval
  - Glucose-6-phosphate dehydrogenase (G6PD) deficiency
  - Myasthenia gravis
  - Known hypersensitivity to quinine, mefloquine, or quinidine
  - Optic neuritis
- Boxed warning(s): Qualaquin use for the treatment or prevention of nocturnal leg cramps may result in serious and life-threatening hematologic reactions, including thrombocytopenia and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP). Chronic renal impairment associated with the development of TTP has been reported. The risk associated with Qualaquin use in the absence of evidence of its effectiveness in the treatment or prevention of nocturnal leg cramps outweighs any potential benefit.

Appendix D: General Information
- For more information on the treatment of malaria, refer to the CDC website: [https://www.cdc.gov/malaria/resources/pdf/treatment_guidelines_101819.pdf](https://www.cdc.gov/malaria/resources/pdf/treatment_guidelines_101819.pdf)
- For more information on the treatment of babesiosis, refer to the CDC website: [https://www.cdc.gov/parasites/babesiosis/health_professionals/index.html](https://www.cdc.gov/parasites/babesiosis/health_professionals/index.html)
V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria</td>
<td>Adults (≥ 16 years of age): 648 mg (two capsules) PO Q8h for 7 days For chloroquine-resistant strains of <em>P. vivax</em>: use concurrently with primaquine phosphate for 14 days plus either tetracycline or doxycycline for 7 days For chloroquine-resistant strains of <em>P. falciparum</em>: use concurrently with tetracycline, clindamycin, or doxycycline for 7 days for chloroquine-resistant infections or infections of unknown resistance</td>
<td>1,944 mg/day</td>
</tr>
<tr>
<td>Babesiosis</td>
<td>Adults: 648 mg PO TID-QID with concurrent administration of clindamycin IV for 7 - 10 days</td>
<td>1,944 mg/day</td>
</tr>
</tbody>
</table>

VI. Product Availability
Capsule: 324 mg

VII. References

Reviews, Revisions, and Approvals

| Policy created: adapted from previously approved policies HIM.PA.144 and CP.CPA.143 (both to be retired); HIM: no significant change from previously approved policy; Commercial: added redirection to formulary antimalarial agent; references reviewed and updated. | 09.10.18 | 11.18 |
| 2Q 2019 annual review: no significant changes; references reviewed and updated. | 02.05.19 | 05.19 |
| 2Q 2020 annual review: added specification of malaria strains to criteria; references reviewed and updated. | 02.05.20 | 05.20 |
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members
and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.